Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Merck
AstraZeneca
Baxter
Moodys

Last Updated: October 1, 2022

NETSPOT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Netspot, and what generic alternatives are available?

Netspot is a drug marketed by Aaa Usa Inc and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-one patent family members in nineteen countries.

The generic ingredient in NETSPOT is gallium dotatate ga-68. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the gallium dotatate ga-68 profile page.

DrugPatentWatch® Generic Entry Outlook for Netspot

Netspot was eligible for patent challenges on June 1, 2020.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 10, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for NETSPOT
International Patents:31
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 4
What excipients (inactive ingredients) are in NETSPOT?NETSPOT excipients list
DailyMed Link:NETSPOT at DailyMed
Drug patent expirations by year for NETSPOT
DrugPatentWatch® Estimated Generic Entry Opportunity Date for NETSPOT
Generic Entry Date for NETSPOT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NETSPOT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Assistance Publique - Hôpitaux de ParisPhase 3
University of Alabama at BirminghamEarly Phase 1
West Virginia UniversityPhase 2

See all NETSPOT clinical trials

US Patents and Regulatory Information for NETSPOT

NETSPOT is protected by one US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of NETSPOT is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting NETSPOT

Process for the preparation of complexes of .sup.68Ga
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

FDA Regulatory Exclusivity protecting NETSPOT

FOR USE AFTER RADIOLABELING WITH GA 68, WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT AND PEDIATRIC PATIENTS.
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aaa Usa Inc NETSPOT gallium dotatate ga-68 POWDER;INTRAVENOUS 208547-001 Jun 1, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Aaa Usa Inc NETSPOT gallium dotatate ga-68 POWDER;INTRAVENOUS 208547-001 Jun 1, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for NETSPOT

When does loss-of-exclusivity occur for NETSPOT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 12297008
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 2014003336
Estimated Expiration: See Plans and Pricing

Canada

Patent: 44145
Estimated Expiration: See Plans and Pricing

Patent: 45484
Estimated Expiration: See Plans and Pricing

China

Patent: 3889930
Estimated Expiration: See Plans and Pricing

Colombia

Patent: 20857
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 42017
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 42017
Estimated Expiration: See Plans and Pricing

Patent: 55168
Estimated Expiration: See Plans and Pricing

Patent: 18991
Estimated Expiration: See Plans and Pricing

India

Patent: 97CHN2014
Estimated Expiration: See Plans and Pricing

Israel

Patent: 0904
Estimated Expiration: See Plans and Pricing

Patent: 5849
Estimated Expiration: See Plans and Pricing

Patent: 5979
Estimated Expiration: See Plans and Pricing

Italy

Patent: 20110180
Estimated Expiration: See Plans and Pricing

Japan

Patent: 61610
Estimated Expiration: See Plans and Pricing

Patent: 14524423
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 0081
Estimated Expiration: See Plans and Pricing

Patent: 14001691
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 2071
Estimated Expiration: See Plans and Pricing

Patent: 8281
Estimated Expiration: See Plans and Pricing

Poland

Patent: 42017
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 42017
Estimated Expiration: See Plans and Pricing

Russian Federation

Patent: 05090
Estimated Expiration: See Plans and Pricing

Patent: 14109381
Estimated Expiration: See Plans and Pricing

Patent: 16144237
Estimated Expiration: See Plans and Pricing

Patent: 20120802
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 1401789
Estimated Expiration: See Plans and Pricing

Spain

Patent: 60231
Estimated Expiration: See Plans and Pricing

Patent: 35581
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NETSPOT around the world.

Country Patent Number Title Estimated Expiration
Portugal 2742017 See Plans and Pricing
Canada 3045484 PROCEDE POUR LA PREPARATION DE COMPLEXES DE 68GA (PROCESS FOR THE PREPARATION OF COMPLEXES OF 68GA) See Plans and Pricing
Denmark 2742017 See Plans and Pricing
European Patent Office 2742017 PROCÉDÉ POUR LA PRÉPARATION DE COMPLEXES DE 68GA (PROCESS FOR THE PREPARATION OF COMPLEXES OF 68GA) See Plans and Pricing
Mexico 370081 PROCEDIMIENTO PARA LA PREPARACION DE COMPLEJOS DE 68GA. (PROCESS FOR THE PREPARATION OF COMPLEXES OF 68GA.) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Dow
Baxter
Johnson and Johnson
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.